OTCMKTS:EPRSQ - Epirus Biopharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.0003 0.00 (0.00 %)
(As of 01/23/2019 06:04 AM ET)
Previous Close$0.0003
Today's Range$0.0003 - $0.0017
52-Week Range$0.0001 - $0.0070
Volume745 shs
Average Volume24,486 shs
Market Capitalization$7,854.00
P/E RatioN/A
Dividend YieldN/A
Beta1.94
EPIRUS Biopharmaceuticals, Inc. is a biopharmaceutical company, which focuses on building a biosimilar business. It focuses on biosimilars, which are biologic drugs that are demonstrated to be highly similar to a previously approved biologic drug, known as a reference product. The company was founded on November 26, 2008 and is headquartered in Boston, MA.

Receive EPRSQ News and Ratings via Email

Sign-up to receive the latest news and ratings for EPRSQ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:EPRSQ
Previous SymbolNASDAQ:EPRS
CUSIPN/A
Phone617-600-3497

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$7,854.00
OptionableNot Optionable

Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) Frequently Asked Questions

What is Epirus Biopharmaceuticals' stock symbol?

Epirus Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "EPRSQ."

How were Epirus Biopharmaceuticals' earnings last quarter?

Epirus Biopharmaceuticals Inc (OTCMKTS:EPRSQ) posted its quarterly earnings data on Wednesday, August, 20th. The biopharmaceutical company reported ($1.52) EPS for the quarter, missing analysts' consensus estimates of ($1.20) by $0.32. View Epirus Biopharmaceuticals' Earnings History.

Has Epirus Biopharmaceuticals been receiving favorable news coverage?

Press coverage about EPRSQ stock has been trending positive on Wednesday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Epirus Biopharmaceuticals earned a coverage optimism score of 2.8 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an effect on the stock's share price in the immediate future.

Who are some of Epirus Biopharmaceuticals' key competitors?

Who are Epirus Biopharmaceuticals' key executives?

Epirus Biopharmaceuticals' management team includes the folowing people:
  • Mr. Jeff Kagy, VP of HR & Admin.
  • Jason Yap, Head of Global Regulatory Affairs and Sr. Director
  • Dr. Louis Boon, Head of CLG, Bioassay & Process Devel.
  • Emile Van Corven Ph.D., Head of Analytical Devel. and Downstream PD
  • Dr. Mark Melville Ph.D., Sr. Director of Process Devel.

How do I buy shares of Epirus Biopharmaceuticals?

Shares of EPRSQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Epirus Biopharmaceuticals' stock price today?

One share of EPRSQ stock can currently be purchased for approximately $0.0003.

How big of a company is Epirus Biopharmaceuticals?

Epirus Biopharmaceuticals has a market capitalization of $7,854.00.

What is Epirus Biopharmaceuticals' official website?

The official website for Epirus Biopharmaceuticals is http://www.epirusbiopharma.com.

How can I contact Epirus Biopharmaceuticals?

Epirus Biopharmaceuticals' mailing address is 699 BOYLSTON ST 8TH FLOOR, BOSTON MA, 02116. The biopharmaceutical company can be reached via phone at 617-600-3497 or via email at [email protected]


MarketBeat Community Rating for Epirus Biopharmaceuticals (OTCMKTS EPRSQ)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  66 (Vote Outperform)
Underperform Votes:  60 (Vote Underperform)
Total Votes:  126
MarketBeat's community ratings are surveys of what our community members think about Epirus Biopharmaceuticals and other stocks. Vote "Outperform" if you believe EPRSQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPRSQ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel